Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells

Brain Tumor Pathology volume 37, pages41–49(2020)Cite this article

Abstract

Although chemoimmunotherapy often lengthens glioblastoma (GBM) survival, early relapses remain problematic as immunosuppressive M2 macrophages (Mϕ) that function via inhibitory cytokine and PD-L1 production cause immunotherapy resistance. Here, we detail anti-PD-L1 antibody effects on the tumor microenvironment, including Mϕ infiltration, using a temozolomide (TMZ)-treated glioma model. In addition, we tested combinations of anti-PD-L1 antibody and the M2Mϕ inhibitor IPI-549 on tumor growth. We simulated late TMZ treatment or relapse stage, persistent GBM cells by generating TMZ-resistant TS (TMZRTS) cells. M2Mϕ-associated cytokine production and PD-L1 expression in these cells were investigated. TMZRTS cells were then subcutaneously implanted into C57BL/6 mice to determine the effectiveness of an anti-PD-L1 antibody and/or IPI-549 treatment on infiltration of CD163-positive Mϕ, usually considered as an M2Mϕ marker into tumor tissues. CD163 expression in samples from human GBM patients were also evaluated. CD163-positive Mϕ heavily infiltrated TMZRS tumor tissues after in vivo anti-PD-L1 antibody treatment. Tumor growth was strongly inhibited by anti-PD-L1 antibody and IPI-549 combination therapy. Anti-PD-L1 antibody treatment significantly reduced infiltration of CD163-positive Mϕ into tumors, while combined PD-L1 antibody and IPI-549 therapy remarkably inhibited tumor growth. These therapies may be useful for recurrent or chronic GBM after TMZ treatment, but clinical safety and effectiveness studies are needed.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

FRT:

Fractionated radiotherapy

GBM:

Glioblastoma multiforme

IHC:

Immunohistochemistry

MGMT:

O6-Methylguanine-DNA methyltransferase

PD-1:

Programmed cell death 1

PD-L1:

PD-1 ligand

TIL:

Tumor-infiltrating lymphocytes

Mϕ:

Macrophage

TMZ:

Temozolomide

References

  1. 1.

    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363(8):711–723

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

    PubMed  Google Scholar 

  5. 5.

    Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372(4):311–319

    PubMed  Google Scholar 

  6. 6.

    Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471

    CAS  PubMed  Google Scholar 

  7. 7.

    Powles T, Durán I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748–757

    CAS  PubMed  Google Scholar 

  8. 8.

    Cohen EEW, Soulières D, Tourneau C, KEYNOTE-040 investigators et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167):156–167

    CAS  PubMed  Google Scholar 

  9. 9.

    Omuro A, Vlahovic G, Lim M et al (2018) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 20(5):674–686

    CAS  PubMed  Google Scholar 

  10. 10.

    Zhao J, Chen AX, Gartrell RD et al (2019) Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 25(3):462–469

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Shen X, Zhao B (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362:k3529

    PubMed  PubMed Central  Google Scholar 

  12. 12.

    Feng YY, Griffith OL, Griffith M (2017) Clinical implications of neoepitope landscapes for adult and pediatric cancers. Genome Med 9(1):77

    PubMed  PubMed Central  Google Scholar 

  13. 13.

    Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909–1920

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burdenand response rate to PD-1 inhibition. N Engl J Med 377(25):2500–2501

    PubMed  PubMed Central  Google Scholar 

  15. 15.

    Howitt BE, Shukla SA, Sholl LM et al (2015) Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1(9):1319–1323

    PubMed  Google Scholar 

  16. 16.

    Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18(9):1182–1191

    CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Chae YK, Anker JF, Bais P et al (2017) Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget 9(8):7949–7960

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Prelaj A, Tay R, Ferrara R et al (2019) Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 106:144–159

    CAS  PubMed  Google Scholar 

  20. 20.

    Miyazaki T, Ishikawa E, Matsuda M et al (2017) Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol. 133(2):277–285

    CAS  PubMed  Google Scholar 

  21. 21.

    Osuka S, Van Meir EG (2017) Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest. 127(2):415–426

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Jhaveri N, Chen TC, Hofman FM (2016) Tumor vasculature and glioma stem cells: contributions to glioma progression. Cancer Lett. 380(2):545–551

    CAS  PubMed  Google Scholar 

  23. 23.

    Silver DJ, Sinyuk M, Vogelbaum MA et al (2016) The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol. 18(2):153–159

    PubMed  Google Scholar 

  24. 24.

    Chen Z, Feng X, Herting CJ et al (2017) Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res. 77(9):2266–2278

    CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Chen Z, Hambardzumyan D (2018) Immune microenvironment in glioblastoma subtypes. Front Immunol. 9:1004

    PubMed  PubMed Central  Google Scholar 

  26. 26.

    Nusblat LM, Carroll MJ, Roth CM (2017) Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol. 40(5):471–482

    CAS  Google Scholar 

  27. 27.

    Evans CA, Liu T, Lescarbeau A et al (2016) Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med Chem Lett. 7(9):862–867

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Hartley GP, Chow L, Ammons DT et al (2018) Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. Cancer Immunol Res. 6(10):1260–1273

    CAS  PubMed  Google Scholar 

  29. 29.

    Sampetrean O, Saga I, Nakanishi M et al (2011) Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia 13:784–791

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352(10):997–1003

    CAS  PubMed  Google Scholar 

  31. 31.

    Cloughesy TF, Mochizuki AY, Orpilla JR et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 25(3):477–486

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 25(3):470–476

    CAS  PubMed  Google Scholar 

  33. 33.

    Ishikawa E, Tsuboi K, Yamamoto T et al (2007) Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci. 98(8):1226–1233

    CAS  PubMed  Google Scholar 

  34. 34.

    Muragaki Y, Maruyama T, Iseki H et al (2011) Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. J Neurosurg. 115(2):248–255

    PubMed  Google Scholar 

  35. 35.

    Ishikawa E, Muragaki Y, Yamamoto T et al (2014) Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 121(3):543–553

    CAS  PubMed  Google Scholar 

  36. 36.

    Ishikawa E, Yamamoto T, Matsumura A (2017) Prospect of immunotherapy for glioblastoma: tumor vaccine, immune checkpoint inhibitors and combination therapy. Neurol Med Chir (Tokyo). 57(7):321–330

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Blando J, Sharma A, Higa MG et al (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 116(5):1692–1697

    CAS  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Kaneda MM, Messer KS, Ralainirina N et al (2016) PI3Kγ is a molecular switch that controls immune suppression. Nature 539(7629):437–442

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    De Henau O, Rausch M, Winkler D et al (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature 539(7629):443–447

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Barros MH, Hauck F, Dreyer JH et al (2013) Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS ONE 8(11):e80908

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Fujimura T, Kambayashi Y, Fujisawa Y et al (2018) Tumor-associated macrophages: therapeutic targets for skin cancer. Front Oncol 8:3

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Xu C, Chen YP, Du XJ et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Alexander Zaboronok, Department of Neurosurgery, for critical revision. The authors would also like to thank Dr. Bryan J. Mathis of the Medical English Communications Center of the Faculty of Medicine, University of Tsukuba, for language revision.

Author information

Author notes

  1. Tsubasa Miyazaki and Eiichi Ishikawa are co-first authors.

Affiliations

  1. Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

    Tsubasa Miyazaki, Eiichi Ishikawa, Masahide Matsuda, Narushi Sugii, Hedihiro Kohzuki, Hiroyoshi Akutsu, Shingo Takano & Akira Matsumura

  2. Cell-Medicine, Inc, Sengen 2-1-6, Tsukuba Science City, Ibaraki, 305-0047, Japan

    Tsubasa Miyazaki

  3. Department of Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan

    Noriaki Sakamoto

Authors
  1. Tsubasa Miyazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eiichi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahide Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Narushi Sugii
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hedihiro Kohzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroyoshi Akutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noriaki Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shingo Takano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Matsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eiichi Ishikawa.

Ethics declarations

Conflict of interest

This study was supported by a Grant-in-Aid for Scientific Research (Research No. 18K08962) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the project for promotion of practical applications of advanced medical technologies in Tsukuba University Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

About this article

Verify currency and authenticity via CrossMark

Cite this article

Miyazaki, T., Ishikawa, E., Matsuda, M. et al. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol 37, 41–49 (2020). https://doi.org/10.1007/s10014-020-00357-z

Download citation

Keywords

  • Immunotherapy
  • Glioblastoma
  • PD-L1
  • IPI-549
  • M2 macrophage
  • Immune checkpoint inhibitor